Modina (Nimodipine)

Nimodipine, the active ingredient in Modina, is a calcium channel blocker presented as a sterile solution for intracisternal and intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in patients at risk.

GNH USA supplies Modina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine acts on the cerebrovascular system to reduce the risk of vasospasm and related ischemic complications. - Subarachnoid hemorrhage: prevention of delayed cerebral ischemia by reducing vasospasm. - Aneurysmal SAH: reduction of vasospasm‑related neurological deficits. - Neurovascular surgery: support of cerebral blood flow during postoperative recovery.

Adverse reactions may occur with nimodipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with skin reddening. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare but possible cardiac event. - Cardiac arrhythmia: including bradyarrhythmias. - Hepatic dysfunction: abnormal liver enzymes. - Anaphylactic reaction: signs of severe allergy. - Seizures: uncommon neurological event.

Careful assessment and monitoring are required when using nimodipine. - Blood pressure monitoring: check for hypotension during and after infusion. - Concomitant vasodilators: avoid additive blood‑pressure lowering effects. - Hepatic function: assess liver enzymes before initiation. - Elderly patients: use with caution due to increased sensitivity. - Discontinue if severe hypotension occurs: stop infusion and provide supportive care. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine may interact with several medicines that affect its metabolism or cardiovascular effects.

Major Interactions (Avoid): - Other calcium channel blockers: risk of additive hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Beta‑blockers: may enhance bradycardia. - Diuretics: may potentiate hypotensive response.